Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Publication year range
1.
J Ultrasound Med ; 42(8): 1887-1892, 2023 Aug.
Article in English | MEDLINE | ID: mdl-36896883

ABSTRACT

We present a 3-patient case series that support the use of ultrasound guided minimally invasive autopsy (MIA). This technique has a high diagnostic accuracy in specific clinical settings. It makes easier to diagnose pathologies once the patient has died, avoiding body deformation, with a notable reduction in sample processing time compared to the open autopsy study and, therefore, a shorter overall diagnostic response time. MIA shows some similarities with point of care ultrasound (POCUS), like examination protocols or that they can be performed at the bedside.


Subject(s)
Point-of-Care Testing , Ultrasonography, Interventional , Humans , Autopsy/methods , Ultrasonography/methods , Point-of-Care Systems
2.
Drug Target Insights ; 13: 1177392819861987, 2019.
Article in English | MEDLINE | ID: mdl-31320796

ABSTRACT

A 43-year-old man with a history of severe extrinsic allergic asthma treated with once-monthly omalizumab (600 mg) for the last 15 months. He presented to the emergency room with a 2-week history of right lower limb pain and chest pleuritic pain. Computed tomography pulmonary angiography showed bilateral pulmonary embolism with right-sided pulmonary infarction and ultrasound of right lower limb confirmed distal deep vein thrombosis. No other known risk factors were identified. Treatment with omalizumab was stopped during hospitalization. The Naranjo Adverse Drug Reaction (ADR) Probability Scale classifies this as a probable ADR (score of 6). Omalizumab is a humanized monoclonal anti-IgE antibody indicated for the treatment of persistent moderate-to-severe asthma and certain chronic refractory urticaria. The EXCELS study (The Epidemiologic Study of Xolair (omalizumab): Evaluating Clinical Effectiveness and Long-term Safety in Patients with Moderate-to-Severe Asthma), a postmarketing observational cohort study to assess clinical safety profile of omalizumab, showed a significant increase in venous thromboembolism. In conclusion, omalizumab has been associated with arterial and venous thromboembolic events, although the evidence is not definitive.

3.
Rev Argent Microbiol ; 48(2): 119-21, 2016.
Article in Spanish | MEDLINE | ID: mdl-27086257

ABSTRACT

Staphylococcus lugdunensis is a coagulase-negative staphylococcus of growing importance and atypical behavior. The infections caused by this microorganism are becoming more frequent, having a broader spectrum. Psoas abscesses caused by this germ are rare, with few cases reported in the literature. In this work, we present a case of a psoas abscess caused by S. lugdunensis in a patient suffering from diabetes mellitus and rheumatoid arthritis, which was treated with intravenous cloxacillin with a good outcome.


Subject(s)
Psoas Abscess/microbiology , Staphylococcal Infections/microbiology , Staphylococcus lugdunensis/isolation & purification , Anti-Bacterial Agents/therapeutic use , Arthritis, Rheumatoid/complications , Bacterial Typing Techniques , Cloxacillin/therapeutic use , Diabetes Mellitus, Type 2/complications , Epidural Abscess/drug therapy , Epidural Abscess/microbiology , Female , Humans , Immunocompromised Host , Middle Aged , Psoas Abscess/drug therapy , Staphylococcal Infections/drug therapy , Staphylococcus lugdunensis/pathogenicity
SELECTION OF CITATIONS
SEARCH DETAIL
...